Scott Lish Sells 22,727 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) COO Scott Lish sold 22,727 shares of Alphatec stock in a transaction on Friday, June 13th. The shares were sold at an average price of $11.07, for a total transaction of $251,587.89. Following the completion of the sale, the chief operating officer now owns 748,918 shares in the company, valued at $8,290,522.26. The trade was a 2.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Scott Lish also recently made the following trade(s):

• On Monday, May 19th, Scott Lish sold 55,375 shares of Alphatec stock. The shares were sold at an average price of $13.00, for a total value of $719,875.00.
• On Monday, May 5th, Scott Lish sold 12,000 shares of Alphatec stock. The stock was sold at an average price of $12.12, for a total value of $145,440.00.

Alphatec Stock Performance

Shares of ATEC stock traded up $0.05 on Friday, hitting $10.94. The company had a trading volume of 2,080,812 shares, compared to its average volume of 2,061,239. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $13.14. The firm has a market cap of $1.60 billion, a P/E ratio of -9.51 and a beta of 1.10. The stock's 50-day moving average is $11.77 and its two-hundred day moving average is $10.84.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). Alphatec had a negative net margin of 25.77% and a negative return on equity of 1,657.19%. The firm had revenue of $169.18 million for the quarter, compared to analyst estimates of $167.57 million. During the same period in the prior year, the company posted ($0.34) EPS. The business's revenue for the quarter was up 22.2% compared to the same quarter last year. Equities research analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Hedge Funds Weigh In On Alphatec

Hedge funds and other institutional investors have recently bought and sold shares of the company. Comerica Bank raised its position in shares of Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock worth $29,000 after acquiring an additional 1,248 shares in the last quarter. Quarry LP boosted its position in shares of Alphatec by 79.2% during the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company's stock valued at $49,000 after purchasing an additional 2,375 shares in the last quarter. Larson Financial Group LLC acquired a new stake in Alphatec during the first quarter worth approximately $54,000. Lazard Asset Management LLC bought a new stake in Alphatec in the fourth quarter worth approximately $76,000. Finally, AlphaQuest LLC bought a new stake in Alphatec in the fourth quarter worth approximately $80,000. Institutional investors and hedge funds own 66.35% of the company's stock.

Analyst Upgrades and Downgrades

ATEC has been the topic of a number of research reports. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research note on Monday, April 14th. Wall Street Zen upgraded Alphatec from a "sell" rating to a "hold" rating in a report on Friday, February 28th. Needham & Company LLC reiterated a "buy" rating and set a $16.00 target price on shares of Alphatec in a research note on Friday, May 2nd. Piper Sandler reissued an "overweight" rating and set a $15.00 price target (up previously from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Finally, Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 price objective on the stock in a research note on Monday. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $17.89.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.